2024 Virtual Grand Rounds
2024 Virtual Grand Rounds Session 6: May 1, 2024 - Treating Acne with Devices and Contact Dermatitis - What Allergens Should I Care about in 2024?
About
Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:
Wednesday, May 1, 2024
8 PM ET / 5 PM PT
Treating Acne with Devices and Contact Dermatitis
What Allergens Should I Care About in 2024?
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
May 2, 2024
May 2, 2025
Learning Objectives
At the completion of this activity, participants should be better able to:
Identify the most common allergen groups that provoke allergic contact dermatitis
Recognize the potential for systemic exposure to contact allergens can cause a patterned dermatitis
Describe the mechanism of action of lasers and light sources in treating acne.
Incorporate lasers and light sources into acne treatment protocols
Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
David Cohen, MD, MPH
Charles C. and Dorothea E. Harris Professor
Vice Chairman for Clinical Affairs
New York University School of Medicine
New York, NY
Joshua Zeichner, MD
Director of Cosmetic and Clinical Research
Icahn School of Medicine at Mount Sinai
New York, NY
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Advisory Board/Consultant: ASLAN, Almirall, Amgen, Arcutis, Beiersdorf, BMS, Dermavant, EPI
Health, Janssen, LEO Pharma, Mindera, Nimbus, Organon & Co, Sanofi, SUN Pharma, Takeda, Ventyx Biosciences
Board Member: Board of Director Elect, American Academy of Dermatology
Grant/Research Support: Abbvie, ASLAN, Bristol Myers Squibb, Dermavant Sciences, Dermira, Eli
Lilly, Galderma, Incyte, Janssen, LEO Pharma, Meiji Seika Pharma Co, Modernizing Medicine, Nimbus Therapeautics, Novartis, Ortho Dermatologics,
Pfizer, Sanofi, Genzyme, UCB, Ventyx Biosciences
Speakers Bureau: Abbvie, Amgen, BMS, Janssen, Mindera, Organon & Co, Sanofi, Takeda
Other Relationships: Data Safety Monitoring Board: Boehringer Ingelheim, Parexel
Advisory Board/Consultant: Ferndale, Medimetriks, Leo, UCB, Novartis [past], SFJ [past], FIDE, Cosmetic Ingredient Review
Board Member: Board of Directors: Kadmon [past], Timber, Evommune
Shareholder: Kadmon [past], Evommune, Timber
Consultant: Abbvie, Allergan, Arcutis, Beiersdorf, Dermavant, Galderma, Incyte, Kenvue, L'Oreal, Pfizer, Procter & Gamble, Sun, Unilever, UCB
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.